Back to Search Start Over

American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules

Authors :
Hossein Gharib
Enrico Papini
Roberto Valcavi
H. Jack Baskin
Anna Crescenzi
Massimo E. Dottorini
Daniel S. Duick
Rinaldo Guglielmi
Carlos Robert Hamilton
Martha A. Zeiger
Michele Zini
Elise M. Brett
Pauline M. Camacho
Samuel Dagogo-Jack
Vivian Andrew Fonseca
Robert F. Gagel
J. Michael Gonzalez-Campoy
Yehuda Handelsman
R. Mack Harrell
Romesh K. Khardori
Marc J. Laufgraben
Philip Levy
Virginia A. LiVolsi
Jeffrey I. Mechanick
A. Ola Odugbesan
Fernando Ovalle
Steven M. Petak
S. Sethu K. Reddy
Herbert I. Rettinger
Victor Lawrence Roberts
F. John Service
Talla P. Shankar
Joseph J. Torre
Dace L. Trence
Roy E. Weiss
Milton K. Wong
Source :
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 12(1)
Publication Year :
2006

Abstract

Thyroid nodules are common and are frequently benign. Current data suggest that the prevalence of palpable thyroid nodules is 3% to 7% in North America; the prevalence is as high as 50% based on ultrasonography (US) or autopsy data. The introduction of sensitive thyrotropin (thyroid-stimulating hormone or TSH) assays, the widespread application of fine-needle aspiration (FNA) biopsy, and the availability of high-resolution US have substantially improved the management of thyroid nodules. This document was prepared as a collaborative effort between the American Association of Clinical Endocrinologists (AACE) and the Associazione Medici Endocrinologi (AME). Most Task Force members are members of AACE. We have used the AACE protocol for clinical practice guidelines, with rating of available evidence, linking the guidelines to the strength of recommendations. Key observations include the following. Although most patients with thyroid nodules are asymptomatic, occasionally patients complain of dysphagia, dysphonia, pressure, pain, or symptoms of hyperthyroidism or hypothyroidism. Absence of symptoms does not rule out a malignant lesion; thus, it is important to review risk factors for malignant disease. Thyroid US should not be performed as a screening test. All patients with a palpable thyroid nodule, however, should undergo US examination. US-guided FNA (US-FNA) is recommended for nodules > or = 10 mm; US-FNA is suggested for nodules < 10 mm only if clinical information or US features are suspicious. Thyroid FNA is reliable and safe, and smears should be interpreted by an experienced pathologist. Patients with benign thyroid nodules should undergo follow-up, and malignant or suspicious nodules should be treated surgically. A radioisotope scan of the thyroid is useful if the TSH level is low or suppressed. Measurement of serum TSH is the best initial laboratory test of thyroid function and should be followed by measurement of free thyroxine if the TSH value is low and of thyroid peroxidase antibody if the TSH value is high. Percutaneous ethanol injection is useful in the treatment of cystic thyroid lesions; large,symptomatic goiters may be treated surgically or with radioiodine. Routine measurement of serum calcitonin is not recommended. Suggestions for thyroid nodule management during pregnancy are presented. We believe that these guidelines will be useful to clinical endocrinologists, endocrine surgeons, pediatricians, and internists whose practices include management of patients with thyroid disorders. These guidelines are thorough and practical, and they offer reasoned and balanced recommendations based on the best available evidence.

Details

ISSN :
1530891X
Volume :
12
Issue :
1
Database :
OpenAIRE
Journal :
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Accession number :
edsair.doi.dedup.....3dcd18e5fc8df4621f3dcb946e73eaef